Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMED Study
2024-514060-10-00Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Feb 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in triple-negative breast cancer (TNBC) and breast cancer, sponsored by MEDSIR. Primary endpoints: Incidence of grade ≥2 diarrhea at cycle 2 and Incidence of grade ≥3 neutropenia at cycle 2. Started Feb 2023; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2024-514060-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514060-10-00.